Amarin Corporation plc
NASDAQ:AMRNBiotechnology
Healthcare
$11.26 +1.84%
+$0.29 today
- Market cap
- $232.89M
- Beta
- 0.82
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$1.62
52W Low $12.30High $20.90
Volume 0.09M
Average 0.07M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$6.74M
FY 2025 · Annual
Investing Cash Flow
$8.85M
FY 2025 · Annual
Financing Cash Flow
-$2.04M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.73M | (105.74M) | (59.34M) | (82.18M) | (38.8M) |
| Depreciation & Amortization | 2.86M | 3.09M | 2.98M | 3.01M | 3.03M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 17.71M | 13.94M |
| Change in Working Capital | (115.98M) | (104.01M) | 51.27M | 36.17M | 32.28M |
| Accounts Receivables | (8.34M) | 32.98M | (2.33M) | 11.22M | (3.83M) |
| Inventory | (167.05M) | (36.4M) | 56.34M | 105.44M | 34.96M |
| Accounts Payables | 51.51M | (102.67M) | (164.64K) | (77.02M) | 14.54M |
| Other Working Capital | 7.9M | 2.07M | (2.56M) | (3.5M) | (13.39M) |
| Other Non-Cash Items | 38.86M | 26.67M | 12M | (5.73M) | (3.71M) |
| Operating Cash Flow | (66.53M) | (179.98M) | 6.91M | (31.03M) | 6.74M |
| Capital Expenditures | 2 | (2) | (24.1K) | 2 | 0 |
| Acquisitions (Net) | 4K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (290.16M) | (81.58M) | (215.93M) | (278.78M) | (200.94M) |
| Sales of Investments | 394.25M | 257.36M | 190.84M | 232.8M | 209.79M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 104.09M | 175.18M | (25.62M) | (45.98M) | 8.85M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 4.57M | 664.59K | 2.22M | 131.06K | 140.33K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (9.64M) | (1.04M) | (1.99M) | (1.57M) | (2.18M) |
| Financing Cash Flow | (5.07M) | (378.77K) | 230.89K | (1.44M) | (2.04M) |
| Effect of Forex Changes | 3.87K | (3.2K) | 71.37K | 33.01K | (31.6K) |
| Net Change in Cash | 32.49M | (5.18M) | (18.41M) | (78.44M) | 13.52M |
| Free Cash Flow | (66.53M) | (179.98M) | 6.88M | (31.02M) | 6.74M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$38.8M
+ D&A$3.0M
+ Stock-Based Comp$13.9M
+ Deferred Tax$0
+ Working Capital$32.3M
- Other Non-Cash-$3.7M
= Operating Cash Flow$6.7M
- Capex$0
= Free Cash Flow$6.7M
Analysis
FY2025 free cash flow is $6.7M. FCF conversion is -17.4% of net income. Operating cash flow was $6.7M, with capex of $0. The largest bridge item is Working Capital at $32.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Oct 28, 2026 | |
| 10-Q | Quarterly report | Oct 28, 2026 | |
| SC 13D/A | SC 13D/A filing | Aug 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 3, 2026 | |
| 10-Q | Quarterly report | Jul 29, 2026 |
Does AMRN generate free cash flow?
Amarin Corporation plc (AMRN) generated $6.74M of free cash flow in fiscal 2025.
How much operating cash flow does AMRN produce?
Operating cash flow was $6.74M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.